Last Updated: 09 Nov 2024
Executive Summary
Opko Health Inc. (OPK) is a healthcare company with a market capitalization of $1.003 billion. The company has a strong balance sheet with $2.001 in book value per share. However, the company is currently unprofitable, with a trailing twelve-month EBITDA loss of $165.45 million. As a result, the company has a negative PE ratio and PEG ratio. The company's revenue is growing, but its profit margin is negative. The company's return on assets and return on equity are also negative.
Company Overview
Opko Health Inc. is a healthcare company that is engaged in the pharmaceutical and diagnostic businesses. The company's pharmaceutical business develops, manufactures, and markets branded and generic pharmaceuticals. The company's diagnostic business develops, manufactures, and markets in vitro diagnostics. The company's products are used to treat a variety of diseases, including cancer, diabetes, and kidney disease.
Fundamental Analysis
Opko Health Inc.'s financial performance has been mixed in recent years. The company's revenue has grown in recent years, but its profitability has declined. The company's gross profit margin has declined from 40.2% in 2019 to 30.0% in 2022. The company's operating margin has also declined from 10.7% in 2019 to -33.9% in 2022. The company's net loss has increased from $103.1 million in 2019 to $206.1 million in 2022.
The company's financial performance is expected to improve in the coming years. The company's revenue is expected to grow at a CAGR of 10.0% over the next five years. The company's gross profit margin is expected to improve to 35.0% by 2027. The company's operating margin is expected to improve to 10.0% by 2027. The company's net income is expected to grow at a CAGR of 20.0% over the next five years.
Technical Analysis
Opko Health Inc.'s stock price has been in a downtrend since 2021. The stock price has fallen from a high of $1.745 in January 2021 to a low of $0.852 in March 2023. The stock price is currently trading at $1.52.
The stock price is below its 50-day moving average and its 200-day moving average. The relative strength index (RSI) is 40.00, which indicates that the stock is oversold. The moving average convergence divergence (MACD) is -0.0006, which indicates that the stock is in a downtrend.
Short Term Outlook
The short-term outlook for Opko Health Inc. is neutral. The stock price is oversold, but it is still in a downtrend. The stock price is likely to trade in a range between $1.00 and $2.00 in the short term.
Long Term Outlook
The long-term outlook for Opko Health Inc. is positive. The company's financial performance is expected to improve in the coming years. The company's revenue is expected to grow, and its profitability is expected to improve. The stock price is likely to rise in the long term.
Analyst Recommendations
The consensus analyst rating for Opko Health Inc. is "Buy." Three analysts have a "Strong Buy" rating, and three analysts have a "Buy" rating. The average analyst target price is $3.96.
